XML 83 R66.htm IDEA: XBRL DOCUMENT v3.20.4
Restructuring (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
plan
Dec. 31, 2019
USD ($)
Restructuring and Related Cost, Expected Number of Positions Eliminated | plan     200  
Restructuring Charges [1] $ 20 $ 385 $ 110 $ 3,328
Restructuring Costs 20 (448) 110 667
Restructuring Costs LTD Since Plan Inception     43,961  
Restructuring Costs 20 (448) 110 667
Restructuring Charges [1] $ 20 $ 385 $ 110 $ 3,328
Restructuring and Related Activities Disclosure [Text Block]     Restructuring
Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency.
Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,961 related to these restructuring actions, of which $31,660 was recorded as restructuring expenses and $12,301 was recorded in cost of revenues, with a total of $34,062, $7,568 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,663. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.
Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at December 31, 2020 and March 31, 2020 are not material.
For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. 		 
Operating Income (Loss) [Member]        
Restructuring Costs     $ 31,660  
Restructuring Costs     31,660  
Cost of Sales [Member]        
Restructuring Costs     12,301  
Restructuring Costs     12,301  
Applied Sterilization Technologies [Member]        
Restructuring Costs     7,568  
Restructuring Costs     7,568  
Life Science Member [Member]        
Restructuring Costs     668  
Restructuring Costs     668  
Healthcare        
Restructuring Costs     34,062  
Restructuring Costs     34,062  
Corporate Segment [Member]        
Restructuring Costs     1,663  
Restructuring Costs     $ 1,663  
[1] For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring"